Is PYPD or SGHT more profitable?

PolyPid has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Sight Sciences -46.83% -52.34% -28.49%

Does the media prefer PYPD or SGHT?

In the previous week, Sight Sciences had 3 more articles in the media than PolyPid. MarketBeat recorded 7 mentions for Sight Sciences and 4 mentions for PolyPid. PolyPid's average media sentiment score of 1.13 beat Sight Sciences' score of 0.50 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PYPD or PROF more profitable?

PolyPid has a net margin of 0.00% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Profound Medical -206.76% -78.88% -64.06%

Does the media refer more to PYPD or PROF?

In the previous week, PolyPid and PolyPid both had 4 articles in the media. PolyPid's average media sentiment score of 1.13 beat Profound Medical's score of 0.50 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PYPD or TLSI?

In the previous week, PolyPid had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 4 mentions for PolyPid and 3 mentions for TriSalus Life Sciences. PolyPid's average media sentiment score of 1.13 beat TriSalus Life Sciences' score of 0.46 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PYPD or TMCI?

In the previous week, PolyPid had 2 more articles in the media than Treace Medical Concepts. MarketBeat recorded 4 mentions for PolyPid and 2 mentions for Treace Medical Concepts. PolyPid's average media sentiment score of 1.13 beat Treace Medical Concepts' score of 0.00 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Treace Medical Concepts 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SMTI or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -31.23% -3.19% -0.56% PolyPid N/A -241.96% -126.91%

Does the media prefer SMTI or PYPD?

In the previous week, Sanara MedTech had 8 more articles in the media than PolyPid. MarketBeat recorded 12 mentions for Sanara MedTech and 4 mentions for PolyPid. PolyPid's average media sentiment score of 1.13 beat Sanara MedTech's score of 0.00 indicating that PolyPid is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral PolyPid 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PolyPid (PYPD) Competitors

$4.29 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.36 +0.07 (+1.52%)

As of 07/31/2026 07:34 PM Eastern

Compare

PYPD vs. SGHT, PROF, TLSI, TMCI, and SMTI

Should you buy PolyPid stock or one of its competitors? MarketBeat compares PolyPid with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PolyPid include Sight Sciences (SGHT), Profound Medical (PROF), TriSalus Life Sciences (TLSI), Treace Medical Concepts (TMCI), and Sanara MedTech (SMTI).

How does PolyPid compare to Sight Sciences?

PolyPid (NASDAQ:PYPD) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

PolyPid has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Sight Sciences	$77.36M	3.70	-$38.43M	-$0.71	N/A

PolyPid has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Sight Sciences	-46.83%	-52.34%	-28.49%

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PolyPid presently has a consensus target price of $11.33, indicating a potential upside of 164.18%. Sight Sciences has a consensus target price of $7.75, indicating a potential upside of 47.34%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts plainly believe PolyPid is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Sight Sciences had 3 more articles in the media than PolyPid. MarketBeat recorded 7 mentions for Sight Sciences and 4 mentions for PolyPid. PolyPid's average media sentiment score of 1.13 beat Sight Sciences' score of 0.50 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PolyPid has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

Summary

Sight Sciences beats PolyPid on 9 of the 15 factors compared between the two stocks.

How does PolyPid compare to Profound Medical?

PolyPid (NASDAQ:PYPD) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

PolyPid has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PolyPid presently has a consensus price target of $11.33, indicating a potential upside of 164.18%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 55.83%. Given PolyPid's higher possible upside, equities analysts plainly believe PolyPid is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

PolyPid has a net margin of 0.00% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Profound Medical	-206.76%	-78.88%	-64.06%

PolyPid has higher earnings, but lower revenue than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Profound Medical	$18.81M	14.26	-$42.57M	-$1.24	N/A

In the previous week, PolyPid and PolyPid both had 4 articles in the media. PolyPid's average media sentiment score of 1.13 beat Profound Medical's score of 0.50 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PolyPid beats Profound Medical on 8 of the 15 factors compared between the two stocks.

How does PolyPid compare to TriSalus Life Sciences?

PolyPid (NASDAQ:PYPD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PolyPid currently has a consensus target price of $11.33, indicating a potential upside of 164.18%. TriSalus Life Sciences has a consensus target price of $7.50, indicating a potential upside of 65.20%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts clearly believe PolyPid is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

PolyPid has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
TriSalus Life Sciences	$45.15M	6.18	-$39.23M	-$1.41	N/A

PolyPid has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

PolyPid has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

In the previous week, PolyPid had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 4 mentions for PolyPid and 3 mentions for TriSalus Life Sciences. PolyPid's average media sentiment score of 1.13 beat TriSalus Life Sciences' score of 0.46 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PolyPid beats TriSalus Life Sciences on 11 of the 15 factors compared between the two stocks.

How does PolyPid compare to Treace Medical Concepts?

PolyPid (NASDAQ:PYPD) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, PolyPid had 2 more articles in the media than Treace Medical Concepts. MarketBeat recorded 4 mentions for PolyPid and 2 mentions for Treace Medical Concepts. PolyPid's average media sentiment score of 1.13 beat Treace Medical Concepts' score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Treace Medical Concepts	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PolyPid has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Treace Medical Concepts	$212.69M	1.31	-$59M	-$0.97	N/A

PolyPid currently has a consensus target price of $11.33, indicating a potential upside of 164.18%. Treace Medical Concepts has a consensus target price of $4.97, indicating a potential upside of 15.31%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts plainly believe PolyPid is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

26.5% of PolyPid shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PolyPid has a net margin of 0.00% compared to Treace Medical Concepts' net margin of -29.44%. Treace Medical Concepts' return on equity of -67.04% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

PolyPid has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Summary

PolyPid beats Treace Medical Concepts on 10 of the 15 factors compared between the two stocks.

How does PolyPid compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Sanara MedTech currently has a consensus price target of $35.00, indicating a potential upside of 3.37%. PolyPid has a consensus price target of $11.33, indicating a potential upside of 164.18%. Given PolyPid's stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.20
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Sanara MedTech had 8 more articles in the media than PolyPid. MarketBeat recorded 12 mentions for Sanara MedTech and 4 mentions for PolyPid. PolyPid's average media sentiment score of 1.13 beat Sanara MedTech's score of 0.00 indicating that PolyPid is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
PolyPid	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PolyPid has lower revenue, but higher earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$107.48M	2.89	-$37.56M	-$3.77	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

Sanara MedTech has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
PolyPid	N/A	-241.96%	-126.91%

Summary

PolyPid beats Sanara MedTech on 10 of the 16 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$81.87M	$11.72B	$6.85B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-2.25	799.05	282.30	24.66
Price / Sales	N/A	753.67	564.25	75.48
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	6.22	10.35	10.98	6.07
Net Income	-$34.17M	$2.82B	$3.49B	$347.99M
7 Day Performance	7.79%	-0.10%	-0.60%	-0.44%
1 Month Performance	-14.54%	-3.95%	-5.19%	-4.81%
1 Year Performance	25.81%	156.15%	62.02%	18.61%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYPD PolyPid	3.4099 of 5 stars	$4.29 flat	$11.33 +164.2%	+25.8%	$81.87M	N/A	N/A	80	Gap Up
SGHT Sight Sciences	3.0433 of 5 stars	$5.30 +3.5%	$7.75 +46.2%	+60.9%	$278.58M	$77.36M	N/A	210	Upcoming Earnings
PROF Profound Medical	2.3078 of 5 stars	$7.25 -1.1%	$11.50 +58.6%	+34.2%	$266.38M	$16.10M	N/A	150	Upcoming Earnings
TLSI TriSalus Life Sciences	2.3766 of 5 stars	$4.33 +0.2%	$7.50 +73.2%	+8.6%	$265.32M	$45.15M	N/A	106	News Coverage Upcoming Earnings
TMCI Treace Medical Concepts	1.7085 of 5 stars	$4.01 -1.7%	$4.97 +23.9%	-19.3%	$264.68M	$212.69M	N/A	250	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors

PYPD vs. SGHT, PROF, TLSI, TMCI, and SMTI

How does PolyPid compare to Sight Sciences?

Summary

How does PolyPid compare to Profound Medical?

Summary

How does PolyPid compare to TriSalus Life Sciences?

Summary

How does PolyPid compare to Treace Medical Concepts?

Summary

How does PolyPid compare to Sanara MedTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PolyPid (PYPD) Competitors

PYPD vs. SGHT, PROF, TLSI, TMCI, and SMTI

How does PolyPid compare to Sight Sciences?

Which has better valuation & earnings, PYPD or SGHT?

Is PYPD or SGHT more profitable?

Do institutionals and insiders believe in PYPD or SGHT?

Do analysts prefer PYPD or SGHT?

Does the media prefer PYPD or SGHT?

Which has more risk and volatility, PYPD or SGHT?

Summary

How does PolyPid compare to Profound Medical?

Which has more volatility & risk, PYPD or PROF?

Do insiders and institutionals believe in PYPD or PROF?

Do analysts recommend PYPD or PROF?

Is PYPD or PROF more profitable?

Which has better valuation and earnings, PYPD or PROF?

Does the media refer more to PYPD or PROF?

Summary

How does PolyPid compare to TriSalus Life Sciences?

Do insiders & institutionals believe in PYPD or TLSI?

Do analysts recommend PYPD or TLSI?

Which has higher valuation & earnings, PYPD or TLSI?

Is PYPD or TLSI more profitable?

Which has more volatility and risk, PYPD or TLSI?

Does the media prefer PYPD or TLSI?

Summary

How does PolyPid compare to Treace Medical Concepts?

Does the media refer more to PYPD or TMCI?

Which has stronger earnings & valuation, PYPD or TMCI?

Do analysts rate PYPD or TMCI?

Do institutionals & insiders hold more shares of PYPD or TMCI?

Is PYPD or TMCI more profitable?

Which has more risk & volatility, PYPD or TMCI?

Summary

How does PolyPid compare to Sanara MedTech?

Do analysts prefer SMTI or PYPD?

Does the media prefer SMTI or PYPD?

Do institutionals and insiders believe in SMTI or PYPD?

Which has better earnings & valuation, SMTI or PYPD?

Which has more volatility and risk, SMTI or PYPD?

Is SMTI or PYPD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools